# Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

> **NCT05504083** · PHASE2 · COMPLETED · sponsor: **InventisBio Co., Ltd** · enrollment: 121 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** D-0120
- **DRUG:** Benzbromarone

## Key facts

- **NCT ID:** NCT05504083
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-28
- **Primary completion:** 2024-05-18
- **Final completion:** 2024-05-18
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504083, "Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05504083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*